AstraZeneca (GB:AZN) has released an update.
AstraZeneca’s drug Imfinzi, in combination with chemotherapy, has been approved by the FDA for the treatment of advanced or recurrent endometrial cancer with mismatch repair deficiency. The DUO-E Phase III trial demonstrated that this treatment significantly reduces the risk of disease progression or death by 58%. The approval marks a significant development in addressing the urgent need for new treatments in combating the fourth most common cancer in US women.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
